In fact, SLC7A5 has been considered a potential therapeutic target for cancer treatment in humans (53–55) and its specific inhibitor, JPH203 (KYT-0353) is currently undergoing a Phase I clinical trial in humans as a novel adjuvant treatment for solid tumors (25). This evidence concerns the gene SLC7A5 and cancer.